Can MYC be drugged directly, and will patients tolerate it?
MYC drives half of all cancers but has no pocket for a drug and is needed by normal cells too. The first direct MYC blockers are in trials; the question is whether there is a therapeutic window.
OMO-103 (Omomyc) showed safety and disease stabilisation in phase 1; MYC degraders and MAX stabilisers follow. Mouse Omomyc studies showed reversible, tolerable toxicity in proliferating tissues, but human tolerance at effective doses is unproven.
Pages like this
not linked directly; found by shared links- IdeaCut the nerve supply to tumours with old drugs
Shares Pancreatic ductal adenocarcinoma and the tags mechanism, open-question.
- IdeaIs aneuploidy itself a druggable vulnerability?
Shares Triple-negative breast cancer (TNBC) and the tags mechanism, open-question.
- IdeaTreat cachexia before it starts
Shares Pancreatic ductal adenocarcinoma and the tags mechanism, open-question.
- IdeaOne-two punch: clear senescent cells after chemotherapy
Shares Triple-negative breast cancer (TNBC) and the tags mechanism, open-question.
- IdeaWhat decides which disseminated cells ever colonise?
Shares Triple-negative breast cancer (TNBC) and the tags mechanism, open-question.
- IdeaWhich patients' blood clones will become leukaemia after treatment?
Shares the tags mechanism, open-question.
- IdeaGive immunotherapy in the morning
Shares the tags mechanism, open-question.
- IdeaKeep them asleep: dormancy maintenance as adjuvant therapy
Shares the tags mechanism, open-question.